ACUR - Acura Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4500
0.0000 (0.00%)
At close: 11:59AM EST
Stock chart is not supported by your current browser
Previous Close0.4500
Open0.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4500 - 0.4500
52 Week Range0.0600 - 0.6300
Volume1,461
Avg. Volume5,275
Market Cap9.585M
Beta (3Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Acura Pharmaceuticals Announces First Quarter 2019 Financial Results

    PALATINE, Ill., Oct. 01, 2019 -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and.

  • GlobeNewswire

    Acura Pharmaceuticals Announces Fourth Quarter 2018 and Full Year 2018 Financial Results

    PALATINE, Ill., Sept. 16, 2019 -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and.

  • GlobeNewswire

    Acura Pharmaceuticals Engages Catalent Pharma Solutions to Advance Development of LTX-03

    Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today announced that it has engaged Catalent Pharma Solutions, LLC (“Catalent”) to initiate manufacturing scale-up of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets to ultimately be used in clinical testing. Catalent is a leading provider of pharmaceutical contract development and manufacturing services and has the expertise, technologies and scale to move products through development. LIMITxTM Technology is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients, but to also deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose.

  • GlobeNewswire

    Acura Pharmaceuticals Licenses LIMITx™ LTX-03

    Acura Pharmaceuticals, Inc. (OTC Pink: ACUR) today announced a License, Development and Commercialization Agreement (the "Agreement") with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”), a special purpose company representing a consortium of investors that will finance Acura’s operations and completion of development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™ technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. AD Pharma retains commercialization rights from which Acura will receive royalties and potential sales related milestones.

  • OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May
    PR Newswire

    OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May

    NEW YORK , June 5, 2019 /PRNewswire/ --   OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective ...

  • GlobeNewswire

    Acura Pharmaceuticals Announces Third Quarter 2018 Financial Results

    PALATINE, Ill., Nov. 27, 2018 -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial.